JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Uždarymo kaina

15.45 1.64

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.95

Max

15.61

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.2M -12M
Darbuotojai	37
EBITDA	-2.1M -12M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+108.03% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	7.7M 1.3B
Ankstesnė atidarymo kaina	13.81
Ankstesnė uždarymo kaina	15.45

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

3.165 / 3.5827 Palaikymas ir pasipriešinimas

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-01 21:36; UTC

Įsigijimai, susijungimai, perėmimai

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

2026-05-01 20:40; UTC

Įsigijimai, susijungimai, perėmimai

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

2026-05-01 18:37; UTC

Pagrindinės rinkos jėgos

Senseonic Shares Slide on Underwritten Offering Price

2026-05-01 16:46; UTC

Pagrindinės rinkos jėgos

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2026-05-01 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-01 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-01 20:42; UTC

Uždarbis

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

2026-05-01 19:33; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-01 19:33; UTC

Rinkos pokalbiai

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

2026-05-01 19:18; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

2026-05-01 19:13; UTC

Rinkos pokalbiai

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

2026-05-01 18:36; UTC

Uždarbis

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

2026-05-01 18:35; UTC

Uždarbis

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

2026-05-01 18:28; UTC

Uždarbis

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

2026-05-01 18:27; UTC

Rinkos pokalbiai

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

2026-05-01 18:14; UTC

Įsigijimai, susijungimai, perėmimai

Barclays Completes Acquisition of Best Egg

2026-05-01 18:04; UTC

Uždarbis

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

2026-05-01 17:43; UTC

Rinkos pokalbiai

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

2026-05-01 17:37; UTC

Rinkos pokalbiai

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

2026-05-01 17:30; UTC

Rinkos pokalbiai

Uždarbis

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

2026-05-01 17:28; UTC

Rinkos pokalbiai

Uždarbis

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

2026-05-01 17:21; UTC

Rinkos pokalbiai

Uždarbis

Apple Seen Absorbing Higher Memory Costs -- Market Talk

2026-05-01 17:19; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

2026-05-01 16:38; UTC

Rinkos pokalbiai

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

2026-05-01 16:23; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

2026-05-01 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-01 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-01 16:15; UTC

Uždarbis

This AI Stock Is Up 78% This Year. Why It Still Looks Like a Buy. -- Barrons.com

2026-05-01 16:11; UTC

Rinkos pokalbiai

Bank of Canada Committed a 'Messaging Blunder' -- Market Talk

2026-05-01 16:04; UTC

Uždarbis

Exxon Stock Slips. CEO Warns 'Full Impact' of War is Coming. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

108.03% į viršų

12 mėnesių prognozė

Vidutinis 31.6 USD 108.03%

Aukščiausias 40 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.165 / 3.5827Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.